Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


S. Korea Officials Not Considering Tamiflu Compulsory License

This article was originally published in PharmAsia News

Executive Summary

The South Korean government is under pressure to follow the practice of some other Asian countries and issue a compulsory license to allow a generic version of Roche's antiviral flu drug, Tamiflu (oseltamivir). The country has not had a serious debate over compulsory licensing since 2005 when the Korea FDA asked several local drug makers if they could manufacture a generic of Tamiflu to treat avian flu. Sixteen South Korean companies submitted data showing they could make the drug almost immediately. A Health Ministry official said a compulsory license was never debated within the government, but some medical professionals say such a move should be considered to deal with the current H1N1 flu outbreaks. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts